Pharma companies engaging in 'pilotitis'—running random, unscalable AI projects—are destined to fall behind. Sustainable competitive advantage comes from integrating AI across the entire value chain and connecting it to core business outcomes, not from isolated experiments.

Related Insights

New McKinsey research reveals a significant AI adoption gap. While 88% of organizations use AI, nearly two-thirds haven't scaled it beyond pilots, meaning they are not behind their peers. This explains why only 39% report enterprise-level EBIT impact. True high-performers succeed by fundamentally redesigning workflows, not just experimenting.

A significant implementation roadblock is the ownership battle between IT and business functions. IT wants to control infrastructure and moves slowly, taking years. In response, business units run their own unsanctioned initiatives to move quickly, leading to a disconnected and unscalable approach to AI.

Companies that experiment endlessly with AI but fail to operationalize it face the biggest risk of falling behind. The danger lies not in ignoring AI, but in lacking the change management and workflow redesign needed to move from small-scale tests to full integration.

Companies struggle with AI not because of the models, but because their data is siloed. Adopting an 'integration-first' mindset is crucial for creating the unified data foundation AI requires.

Companies run numerous disconnected AI pilots in R&D, commercial, and other silos, each with its own metrics. This fragmented approach prevents enterprise-wide impact and disconnects AI investment from C-suite goals like share price or revenue growth. The core problem is strategic, not technical.

Many firms are stuck in "pilot purgatory," launching numerous small, siloed AI tests. While individually successful, these experiments fail to integrate into the broader business system, creating an illusion of progress without delivering strategic, enterprise-level value.

Many pharma companies have breakthrough AI results in isolated functions, or "pockets of excellence." However, the ultimate competitive advantage will go to the company that first connects these disparate successes into a single, integrated, enterprise-wide AI capability, thereby creating compounded value across the organization.

Many pharma companies allow various departments to run numerous, disconnected AI pilots without a central strategy. This lack of strategic alignment means most pilots fail to move beyond the proof-of-concept stage, with 85% yielding no measurable return on investment.

To maximize AI's impact, don't just find isolated use cases for content or demand gen teams. Instead, map a core process like a campaign workflow and apply AI to augment each stage, from strategy and creation to localization and measurement. AI is workflow-native, not function-native.

Many companies focus on AI models first, only to hit a wall. An "integration-first" approach is a strategic imperative. Connecting disparate systems *before* building agents ensures they have the necessary data to be effective, avoiding the "garbage in, garbage out" trap at a foundational level.